NasdaqGM - Nasdaq Real Time Price USD

XOMA Royalty Corporation (XOMA)

Compare

26.71

+1.31

+(5.16%)

At close: 4:00:01 PM EST

26.70

-0.01

(-0.04%)

After hours: 4:39:26 PM EST

XOMA Royalty Declares Quarterly Preferred Stock Dividends

EMERYVILLE, Calif., Dec. 19, 2024 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (Nasdaq: XOMA) today announced its Board of Directors has authorized the following cash dividends to holders of XOMA’s Series A and Series B Cumulative Preferred Stock: Holders of the 8.625% Series A Cumulative Perpetual Preferred Stock (Nasdaq: XOMAP) shall receive a cash dividend equal to $0.53906 per share. Holders of depositary shares, each representing 1/1000 of a share of XOMA’s 8.375% Series B Cumulative Perpet

GlobeNewswire 26 days ago

XOMA
+5.16%
XOMAO

XOMAP
XOMA Royalty Acquires Pulmokine for $20 Million Adding the Royalty and Milestone Interest in Seralutinib, a Phase 3 Asset, to Its Portfolio

Seralutinib becomes XOMA Royalty’s seventh Phase 3 royalty asset, further building the late-stage pipeline beyond its six current commercial royalty assets Seralutinib is being developed and co-commercialized by Gossamer Bio, Inc., and Chiesi Farmaceutici S.p.A; a Phase 3 study for pulmonary arterial hypertension is ongoing and is expected to read out in the fourth quarter of 20251 XOMA Royalty has the potential to net up to $25 million in milestone payments and earn a low to mid-single digit ro

GlobeNewswire last month

XOMA
+5.16%
XOMAO

XOMAP
What Makes XOMA Royalty (XOMA) a New Buy Stock

XOMA Royalty (XOMA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks 2 months ago

XOMA
+5.16%
XOMA Royalty Corporation (NASDAQ:XOMA) Just Reported Third-Quarter Earnings And Analysts Are Lifting Their Estimates

XOMA Royalty Corporation ( NASDAQ:XOMA ) came out with its third-quarter results last week, and we wanted to see how...

Simply Wall St. 2 months ago

XOMA
+5.16%
XOMAO

XOMAP
XOMA Royalty Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

XOMA Royalty ( NASDAQ:XOMA ) Third Quarter 2024 Results Key Financial Results Revenue: US$7.20m (up by US$6.37m from 3Q...

Simply Wall St. 2 months ago

XOMA
+5.16%
XOMAO

XOMAP
XOMA Royalty (XOMA) Reports Q3 Loss, Tops Revenue Estimates

XOMA Royalty (XOMA) delivered earnings and revenue surprises of 11.36% and 8.06%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks 2 months ago

XOMA
+5.16%
XOMA Royalty: Q3 Earnings Snapshot

EMERYVILLE, Calif. AP) — XOMA Royalty Corporation (XOMA) on Thursday reported a loss of $18.6 million in its third quarter. The Emeryville, California-based company said it had a loss of $1.59 per share.

Associated Press Finance 2 months ago

XOMA
+5.16%
XOMA Royalty Reports Third Quarter 2024 Financial Results and Highlights Recent Activities

Zevra’s MIPLYFFA™ (arimoclomol) received FDA approval and became the sixth commercial asset in XOMA Royalty’s portfolio XOMA Royalty acquired a 50 percent economic interest in TWIST Bioscience’s portfolio of 60-plus licensed early-stage assets across approximately 30 partners Cash receipts totaled $9.9 million in the third quarter, and $42.3 million for the first nine months of 2024 EMERYVILLE, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA), the biotech royalty

GlobeNewswire 2 months ago

XOMA
+5.16%
XOMAO

XOMAP
XOMA Royalty Significantly Expands its Royalty and Milestone Portfolio with the Addition of Over 60 Early-Stage Programs from Twist Bioscience

XOMA Royalty has acquired 50 percent of Twist’s existing royalty and milestone economics for $15 million XOMA Royalty’s portfolio now holds over 100 assets ranging from revenue-generating commercial therapeutics to pre-clinical programs EMERYVILLE, Calif., Oct. 22, 2024 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA) announced today it has entered into a $15 million royalty monetization arrangement with Twist Bioscience Corporation to acquire a 50 percent economic interest in all fut

GlobeNewswire 2 months ago

XOMA
+5.16%
XOMAO

XOMAP
Investors in XOMA Royalty (NASDAQ:XOMA) have seen favorable returns of 72% over the past year

The simplest way to invest in stocks is to buy exchange traded funds. But you can significantly boost your returns by...

Simply Wall St. 2 months ago

XOMA
+5.16%
XOMAO

XOMAP
Zevra’s MIPLYFFA™ (arimoclomol) Receives Approval from U.S. Food and Drug Administration for Use in Patients with Niemann-Pick Disease Type C (NPC)

MIPLYFFA™ is the first therapy approved for use in patients with NPC, a rare genetic disorder XOMA Royalty is entitled to receive a mid-single digit royalty on MIPLYFFA™ sales and up to $52.6 million in milestones MIPLYFFA™ is now the sixth commercial asset in XOMA Royalty’s portfolio EMERYVILLE, Calif., Sept. 23, 2024 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today Zevra Therapeutics has received approval from the U.S. Food and Drug A

GlobeNewswire 3 months ago

XOMA
+5.16%
XOMAO

XOMAP
High Growth Tech Stocks In The United States To Watch

Over the last 7 days, the market has dropped 3.4%, but it has risen by 20% in the last year with earnings forecast to grow by 15% annually. In this dynamic environment, identifying high growth tech stocks that can capitalize on these trends is crucial for investors looking to maximize their returns.

Simply Wall St. 4 months ago

ENFN

DVAX

XOMA
+5.16%
XOMA Royalty to Present at Upcoming Investor Conferences in September

EMERYVILLE, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today members of its Executive Team will participate at the following September 2024 investor conferences: H.C. Wainwright 26th Annual Global Investment Conference taking place September 9-11, 2024, in New York, NY. Owen Hughes, Chief Executive Officer, and Brad Sitko, Chief Investment Officer, will present a corporate overview on Monday, September 9, 2024, at

GlobeNewswire 4 months ago

XOMA
+5.16%
XOMAO

XOMAP
Party Time: Brokers Just Made Major Increases To Their XOMA Royalty Corporation (NASDAQ:XOMA) Earnings Forecasts

Celebrations may be in order for XOMA Royalty Corporation ( NASDAQ:XOMA ) shareholders, with the analysts delivering a...

Simply Wall St. 4 months ago

XOMA
+5.16%
XOMAO

XOMAP
XOMA Royalty Second Quarter 2024 Earnings: Beats Expectations

XOMA Royalty ( NASDAQ:XOMA ) Second Quarter 2024 Results Key Financial Results Revenue: US$11.1m (up by US$9.43m from...

Simply Wall St. 4 months ago

XOMA
+5.16%
XOMAO

XOMAP
XOMA Royalty (XOMA) Reports Q2 Loss, Tops Revenue Estimates

XOMA Royalty (XOMA) delivered earnings and revenue surprises of -7.69% and 32.45%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks 4 months ago

XOMA
+5.16%
XOMA Royalty: Q2 Earnings Snapshot

EMERYVILLE, Calif. AP) — XOMA Royalty Corporation (XOMA) on Tuesday reported second-quarter earnings of $16 million. On a per-share basis, the Emeryville, California-based company said it had net income of 84 cents.

Associated Press Finance 4 months ago

XOMA
+5.16%
XOMA Royalty Reports Second Quarter 2024 Financial Results and Highlights Recent Activities

Cash receipts totaled $22.6 million in 2Q24, inclusive of royalty income and milestones from Day One Pharmaceuticals and Rezolute Expanded the commercial royalty and milestone portfolio with the acquisition of economic interests in XACIATO™ (clindamycin phosphate) vaginal gel 2%, and two novel Phase 3 assets, from Daré Bioscience Completed the acquisition of Kinnate Pharmaceuticals, adding several potential royalty streams, as well as more than $9.5 million in non-dilutive capital EMERYVILLE, Ca

GlobeNewswire 4 months ago

XOMA
+5.16%
XOMAO

XOMAP
ITeos Therapeutics, Inc. (ITOS) Reports Q2 Loss, Tops Revenue Estimates

iTeos Therapeutics (ITOS) delivered earnings and revenue surprises of 82.69% and 733.33%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks 5 months ago

ITOS

XOMA
+5.16%
Xoma (XOMA) Surges 6.4%: Is This an Indication of Further Gains?

Xoma (XOMA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Zacks 5 months ago

BMRN

XOMA
+5.16%

Performance Overview

Return	XOMA	S&P 500
YTD	+2.38%	-1.08%
1-Year	+32.49%	+22.14%
3-Year	+19.08%	+25.41%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

XOMA Royalty Corporation (XOMA)

XOMA Royalty Declares Quarterly Preferred Stock Dividends

XOMA Royalty Acquires Pulmokine for $20 Million Adding the Royalty and Milestone Interest in Seralutinib, a Phase 3 Asset, to Its Portfolio

What Makes XOMA Royalty (XOMA) a New Buy Stock

XOMA Royalty Corporation (NASDAQ:XOMA) Just Reported Third-Quarter Earnings And Analysts Are Lifting Their Estimates

XOMA Royalty Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

XOMA Royalty (XOMA) Reports Q3 Loss, Tops Revenue Estimates

XOMA Royalty: Q3 Earnings Snapshot

XOMA Royalty Reports Third Quarter 2024 Financial Results and Highlights Recent Activities

XOMA Royalty Significantly Expands its Royalty and Milestone Portfolio with the Addition of Over 60 Early-Stage Programs from Twist Bioscience

Investors in XOMA Royalty (NASDAQ:XOMA) have seen favorable returns of 72% over the past year

Zevra’s MIPLYFFA™ (arimoclomol) Receives Approval from U.S. Food and Drug Administration for Use in Patients with Niemann-Pick Disease Type C (NPC)

High Growth Tech Stocks In The United States To Watch

XOMA Royalty to Present at Upcoming Investor Conferences in September

Party Time: Brokers Just Made Major Increases To Their XOMA Royalty Corporation (NASDAQ:XOMA) Earnings Forecasts

XOMA Royalty Second Quarter 2024 Earnings: Beats Expectations

XOMA Royalty (XOMA) Reports Q2 Loss, Tops Revenue Estimates

XOMA Royalty: Q2 Earnings Snapshot

XOMA Royalty Reports Second Quarter 2024 Financial Results and Highlights Recent Activities

ITeos Therapeutics, Inc. (ITOS) Reports Q2 Loss, Tops Revenue Estimates

Xoma (XOMA) Surges 6.4%: Is This an Indication of Further Gains?

Performance Overview